HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression of blood group precursor T antigen as a prognostic marker for human bladder cancer treated by bacillus Calmette-Guerin and interleukin-2.

Abstract
The relationship between T antigen expression in transitional cell carcinoma of the bladder and response to bacillus Calmette-Guerin plus interleukin-2 treatment was studied. A total of 25 patients received combined treatment with bacillus Calmette-Guerin and interleukin-2 at weekly instillations for 6 consecutive weeks and then monthly for 1 year. T antigen expression in all patients was studied before treatment. Of the patients 16 had positive T antigen expression in the tumors: 13 (81%) remained free of tumor for an average of 28 months, 3 had a noninvasive recurrence each at 8 to 27 months (mean 18 months) and all responded well to a repeated treatment cycle. Nine patients were negative for T antigen: 1 (11%) remained free of tumor for 11 months, while 8 had recurrence within 12 months. Of the latter 8 patients 2 had noninvasive recurrence each at 4 to 5 months but they responded to a repeated treatment cycle and remained free of tumor for 4 to 22 months (mean 13 months), 4 had subsequent repeated recurrences at 12 to 41 months (mean 22 months) and 2 had progression to deep invasion resulting in cystectomy at 11 to 12 months. Thus, the disease-free rate (continuous complete response) in patients with tumors positive for T antigen was 81%, while that in patients with tumors negative for T antigen was 11% (p less than 0.005, chi-square test). The over-all response rate in patients with positive and negative tumors to bacillus Calmette-Guerin and interleukin-2 treatment was 100 and 33%, respectively, and that for the total patients was 76%. T antigen may serve as a target recognition structure for effector cells generated by bacillus Calmette-Guerin plus interleukin-2 treatment. This study suggests that T antigen is useful to predict the response of bladder tumors to treatment with bacillus Calmette-Guerin and interleukin-2.
AuthorsJ A Dow, P A di Sant'Agnese, A T Cockett
JournalThe Journal of urology (J Urol) Vol. 142 Issue 4 Pg. 978-81; discussion 981-2 (Oct 1989) ISSN: 0022-5347 [Print] United States
PMID2477561 (Publication Type: Journal Article)
Chemical References
  • Antigens, Tumor-Associated, Carbohydrate
  • BCG Vaccine
  • Biomarkers, Tumor
  • Disaccharides
  • Interleukin-2
  • Thomsen-Friedenreich antigen
Topics
  • Aged
  • Aged, 80 and over
  • Antigens, Tumor-Associated, Carbohydrate
  • BCG Vaccine (therapeutic use)
  • Biomarkers, Tumor
  • Disaccharides (immunology)
  • Female
  • Humans
  • Interleukin-2 (therapeutic use)
  • Male
  • Middle Aged
  • Prognosis
  • Sensitivity and Specificity
  • Staining and Labeling
  • Urinary Bladder Neoplasms (immunology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: